Hematologia Geral
OMS faz recomendação contra o uso de plasma convalescente para tratar COVID-19.
8 Dez, 2021 | 13:22hComunicado de imprensa: WHO recommends against the use of convalescent plasma to treat COVID-19 – World Health Organization
Ver orientação: WHO’s living guidelines on COVID-19 therapeutics
Infográfico: A living WHO guideline on drugs for covid-19 – The BMJ
Comentário no Twitter (fio – clique para saber mais)
Convalescent plasma is a transfusion of blood plasma from someone who has recovered from #COVID19, and is used as a treatment for COVID19 https://t.co/Bobq7OTDGq pic.twitter.com/pfO1sFvUpJ
— World Health Organization (WHO) (@WHO) December 7, 2021
Posicionamento ESC | Seguimento ótimo após embolia pulmonar aguda.
8 Dez, 2021 | 13:09h
Comentário no Twitter
Do you routinely discuss how/when to resume sporting activities and traveling with your PE patients? Or future cardiovascular risk? Check this recent ESC/ERS position paper on optimal follow-up of acute PE for these and other key aspects of counselling: https://t.co/KEQ7FnFwXX
— Erik Klok (@Erik_Klok_MD) December 7, 2021
Outro estudo randomizado mostrou que o plasma convalescente não beneficia pacientes internados com Covid-19.
1 Dez, 2021 | 15:36hConteúdos relacionados:
M-A: Convalescent plasma does not reduce mortality in COVID-19.
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Comentário no Twitter
The TSUNAMI RCT showed that high-titer convalescent plasma (CP) did not reduce the risk of severe respiratory failure or death in hospitalized patients with #COVID19 pneumonia. https://t.co/4q0S2AtfMj
— JAMA Network Open (@JAMANetworkOpen) November 29, 2021
Revisão | Prevenção e tratamento de trombose em pacientes internados com pneumonia por COVID-19.
26 Nov, 2021 | 12:04hRevisão | Doença de Castleman.
26 Nov, 2021 | 11:44hCastleman disease – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)
Infográfico: Castleman Disease (se o acesso a este link for pago, tente este)
Diretriz para o diagnóstico laboratorial da deficiência de ferro em adultos (exceto gestantes) e crianças.
25 Nov, 2021 | 15:07hEstudo de coorte prospectivo mostrou um risco de 3,1% de tromboembolismo venoso recorrente em 90 dias em pacientes com embolia pulmonar subsegmentar tratada sem anticoagulação.
24 Nov, 2021 | 11:20hRisk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
First prospective study including patients with isolated SSPE managed without anticoagulation published in @AnnalsofIM. Rate of recurrent VTE is 3.1% . Nice collaboration between @INNOVTE1 and @canvector funded by @HeartandStroke https://t.co/GdcbM1fRp1 @OttMethodsCentr
— Marc Carrier (@MarcCarrier1) November 23, 2021
M-A | Plasma convalescente não reduz a mortalidade na COVID-19.
22 Nov, 2021 | 09:34hConteúdos relacionados:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
M-A | Ferro por via intravenosa está associado com risco aumentado de infecção em comparação com ferro por via oral ou não reposição, o que deve ser equilibrado com os benefícios potenciais da redução na necessidade de transfusão sanguínea.
19 Nov, 2021 | 12:58hComentário convidado: Intravenous Iron and Infection Risk—Still an Unanswered Question – JAMA Network Open
Comentário no Twitter
In this systematic review and meta-analysis, administration of intravenous iron was associated with an increased risk of infection. This risk must be balanced with the potential benefits of treating anemia and reducing blood transfusion requirements. https://t.co/XkNJKCk7M7
— JAMA Network Open (@JAMANetworkOpen) November 12, 2021
Nova terapia gênica para hemofilia A induz uma expressão sustentada de fatores de coagulação e reduziu os eventos hemorrágicos.
19 Nov, 2021 | 12:51hComunicado de imprensa: Novel gene therapy for hemophilia a leads to sustained expression of clotting factor and reduced bleeding events – Children’s Hospital of Philadelphia
Estudo original: Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A – New England Journal of Medicine
Comentário no Twitter
3.5 years after therapy with factor VIII-containing adeno-associated virus, 16 of 18 men with hemophilia A had enough factor VIII expression that bleeding events were reduced to nearly zero and prophylaxis was discontinued. https://t.co/n3cPyjGDkn pic.twitter.com/vPyz0OmT1S
— NEJM (@NEJM) November 18, 2021